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Acid loading during treatment with sevelamer hydrochloride:
Mechanisms and clinical implications. Short-term and long-
term studies indicate that patients treated with sevelamer hy-
drochloride have lower serum bicarbonate levels than patients
treated with calcium-containing phosphate binders. This ob-
servation has previously been attributed to withdrawal of a
source of base with discontinuation of calcium carbonate or
calcium acetate. However, understanding of the chemistry of
sevelamer hydrochloride suggests at least three potential mech-
anisms whereby it might induce a dietary acid load. Moreover,
preliminary results from an animal model demonstrate that
treatment with sevelamer hydrochloride results in a fall in urine
pH, as well as an increase in urinary ammonium and calcium ex-
cretion consistent with an increase in net acid excretion. Chronic
metabolic acidosis in maintenance dialysis patients is associated
with major systemic effects. It is independently associated with
an increased risk of death in dialysis patients. Metabolic acido-
sis has both catabolic and antianabolic effects that may lead to
a net negative nitrogen balance and total body protein balance.
Metabolic acidosis also leads to physiochemical dissolution of
bone and promotes cell-mediated bone resorption due to en-
hanced osteoclast activity and reduced osteoblast activity. It
may also exacerbate secondary hyperparathyroidism and renal
osteodystrophy. Given the long-term risks of chronic metabolic
acidosis in maintenance dialysis patients, Kidney/Dialysis Out-
come Quality Initiative (K/DOQI) guidelines have recently rec-
ommended maintaining predialysis serum levels of CO2 above
22 mmol/L in order to improve bone histology, and to amelio-
rate excess protein catabolism.
Short-term and long-term studies have demonstrated
that maintenance hemodialysis patients treated with
sevelamer hydrochloride have significantly lower predial-
ysis serum bicarbonate levels than patients treated with
calcium-containing phosphate binders [1, 2]. In the re-
cently published Calcium Acetate Renagel Evaluation
(CARE study), hemodialysis patients were randomized
to treatment with either calcium acetate or sevelamer
hydrochloride [3]. Over the eight-week course of the
study, sevelamer hydrochloride–treated patients had sig-
nificantly lower serum bicarbonate levels than patients
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treated with calcium acetate (Fig. 1A). During weeks one
to eight, mean serum bicarbonate levels ranged from 20.4
to 21.9 mEq/L with calcium acetate compared to 19.2 to
20.2 mEq/L with sevelamer hydrochloride. By the end of
the eight weeks, the serum bicarbonate level increased
to 21.0 ± 2.6 mEq/L (mean ± SD) with calcium acetate,
while it decreased to 19.3 ± 2.7 with sevelamer hydrochlo-
ride. Moreover, sevelamer hydrochloride–treated pa-
tients were significantly more likely to have predialysis
serum bicarbonate levels less than the National Kidney
Foundation Kidney/Dialysis Outcome Quality Initiative
(NFK K/DOQI) recommended guideline of 22 mEq/L
(Fig. 1B).
Potential mechanisms of acid loading during treatment
with sevelamer hydrochloride
In the past, the finding of significantly lower serum
bicarbonate levels in hemodialysis patients treated with
sevelamer hydrochloride has been attributed to the fact
that patients taking this non-calcium, non-aluminum
phosphate binder are often withdrawn from an alkaliniz-
ing agent (carbonate or acetate) in the form of calcium-
containing phosphate binders [4]. However, careful
review of the chemistry of sevelamer hydrochloride sug-
gests at least three potential mechanisms by which its use
might lead to an increase in dietary mineral acid load.
Sevelamer hydrochloride is a quaternary amine anion
exchange resin that has been FDA-approved for use in
dialysis patients as a dietary phosphate binder [5]. It is a
nonabsorbed polymer chain with covalently linked amino
groups, and 40% of these amino groups consist of amine
hydrochloride. Overall, sevelamer contains 17% chloride
by weight. The proposed phosphate-binding model for
sevelamer hydrochloride is shown in Figure 2A. The qua-
ternary amine resin acts as an anion exchanger whereby
monovalent phosphate is bound (via ionic and hydrogen
bonding) in exchange for release of the anion chloride. In
this model, one molecule of hydrochloric acid is liberated
for each molecule of phosphate bound in the gut.
Sevelamer hydrochloride may also exchange chloride
for any other anion available in the gastrointestinal tract.
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Fig. 1. Serum bicarbonate levels during treatment with calcium acetate
or sevelamer hydrochloride in the CARE study. Mean serum bicar-
bonate levels at baseline and weekly during treatment in patients ran-
domized to treatment with either calcium acetate () or sevelamer hy-
drochloride (). At baseline, serum bicarbonate was not significantly
different between the calcium acetate and sevelamer hydrochloride
groups (P value 0.11). However, during treatment mean serum bicar-
bonate levels were significantly lower in the sevelamer group than in the
calcium acetate group (P value < 0.0001 by covariate-adjusted repeated
measures regression) (A). Observed and model-estimated percent of
subjects with serum bicarbonate <22 mEq/L by treatment group and
week. Main treatment effect: P value < 0.0001. Reprinted with permis-
sion from Qunibi WY, Hootkins RE, McDowell LL, et al: Treatment
of hyperphosphatemia in hemodialysis patients: The calcium acetate
Renagel evaluation (CARE study). Kidney Int 65:1914–1926, 2004 (B).
For instance, in the small intestine, the local concentration
of bicarbonate exceeds 100 to 120 mEq/L due to alkaline
secretion from the pancreas, such that the chemical gra-
dient would favor binding of bicarbonate in exchange for
chloride. The elimination of carbonated sevelamer in the
stool would result in gastrointestinal loss of bicarbonate
in excess of chloride loss, thereby leading to metabolic
acidosis via a mechanism similar that which occurs in the
setting of chronic diarrhea (Fig. 2B).
Treatment of hemodialysis patients with sevelamer hy-
drochloride also results in a significant reduction in total
and low-density lipoprotein (LDL) cholesterol [6]. Seve-
lamer hydrochloride is thought to exert its lipid-lowering
effect by acting as a bile acid sequestrant with a mecha-
nism of action similar to cholestyramine [7]. Binding of
bile acids in exchange for chloride would also result in
the net production of one molecule of HCl acid for every
bile acid molecule bound (Fig. 2C). In this regard, treat-
ment of patients with cholestyramine is known to result
in a mineral acid load with development of metabolic
acidosis and hypercalcuria [8–10]. The hypercalciuria is
thought to be the result of chemical buffering of the acid
load in the bone causing net efflux of calcium because
treatment with sodium bicarbonate in an amount equal
to the chloride content of administered cholestyramine
prevents hypercalciuria [10].
Preliminary evidence from an animal model
Preliminary data from our laboratory indicate that nor-
mal rats treated with sevelamer hydrochloride develop
a significant reduction in urine pH (Fig. 3A), a signifi-
cant increase in urinary ammonium excretion (Fig. 3B),
as well as a significant increase in urine calcium excretion
(data not shown) [11]. These data support the concept
that treatment with sevelamer hydrochloride results in a
significant increase in dietary acid load.
Given that sevelamer hydrochloride contains 17%
chloride by weight, and assuming complete exchange of
chloride for phosphate, bicarbonate, or bile acids, each
800 mg tablet of sevelamer hydrochloride could theoret-
ically lead to an acid load equivalent to 4 mEq HCl acid.
Thus, dialysis patients treated with four 800 mg tablets
of sevelamer hydrochloride thrice daily with meals as
a phosphate binder might receive an additional dietary
acid load approaching 46 mEq/day. These considerations
suggest that a widespread shift from use of calcium-
containing phosphate binders to sevelamer hydrochlo-
ride might result in an increase in the prevalence and
severity of chronic metabolic acidosis in the hemodialysis
population. Thus, it is important to consider the potential
clinical implications of inadequately treated metabolic
acidosis in dialysis patients [12].
RISKS OF CHRONIC METABOLIC ACIDOSIS IN
DIALYSIS PATIENTS
Metabolic acidosis is common in patients with chronic
kidney disease and results from reduced renal net acid
excretion due to either defective renal ammoniagenesis
or defective urine acidification. Dialysis therapy, as prac-
ticed today, is often inadequate to correct the metabolic
acidosis associated with uremia. This has important clin-
ical implications because metabolic acidosis, with serum
bicarbonate below 17.5 mEq/L, has been independently
associated with increased risk of death in dialysis patients
[13].
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Fig. 2. Theoretical mechanisms of acid load-
ing during treatment with sevelamer hy-
drochloride. Monovalent phosphate is bound
to the sevelamer polymer via ionic and
hydrogen-bonding interactions in exchange
for release of the leaving anion chlo-
ride. For each phosphate molecule bound,
one molecule of hydrochloride is produced
(A). Exchange of chloride for bicarbon-
ate in the small intestine. Loss of carbon-
ated sevelamer in the stool leads to gas-
trointestinal losses of bicarbonate in excess
of chloride. The net effect is production
of excess HCl acid resulting in metabolic
acidosis by a mechanism akin to development
of nonanion gap metabolic acidosis in the set-
ting of diarrhea (B). Sequestration of bile
acids (cholic acid and chenodeoxycholic acid)
by sevelamer in exchange for release of chlo-
ride. The net effect is the production of one
HCl molecule for every molecule of bile acid
bound (C). CA, carbonic anhydrase; GI, gas-
trointestinal.
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Fig. 3. Rat model demonstrating increased urinary net acid excretion
during treatment with sevelamer hydrochloride. Normal rats (N = 18,
250 g male Sprague-Dawley) were placed on a regular diet for six days
and then divided into three groups of six rats and treated with test
agents admixed with diet for seven days as follows: group 1, seve-
lamer hydrochloride: 1 g/day containing 5 mmol/L chloride (closed
squares); group 2, HCl acid: 5 mmol/day (open squares); and group
3, sodium chloride: 5 mmol/day (open circles). Rats were housed in
metabolic cages to measure 24-hour urine for pH (A) and NH4
+ excre-
tion (lmol/day; measured by ion specific electrode) (B). ∗P < 0.05 vs.
baseline and other treatment groups, †P < 0.05 vs. baseline and NaCl
treatment group, §P < 0.05 vs. baseline and HCl acid treatment groups.
Protein catabolic effects of chronic metabolic acidosis
In normal individuals and patients with chronic kid-
ney disease, metabolic acidosis leads to negative nitro-
gen balance [14, 15]. Both animal and human studies
indicate that metabolic acidosis is associated with pro-
teolysis, and that correction of acidosis, in turn, results in
a decrease in protein degradation. Rats treated with am-
monium chloride demonstrate elevated protein degrada-
tion and amino acid oxidation, which can be prevented by
addition of sodium bicarbonate to the diet [16, 17]. Aci-
dosis has been shown to induce catabolism of essential
amino acids by up-regulating the activity of an enzyme
called branched-chain ketoacid dehydrogenase [18, 19].
Many studies in humans with chronic kidney disease have
demonstrated that metabolic acidosis promotes proteol-
ysis [20–23]. The enhanced muscle protein catabolism in
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Fig. 4. Effects of metabolic acidosis on protein metabolism.
metabolic acidosis appears to be related to an increase in
the activity of the ATP-dependent ubiquitin-proteosome
pathway for protein degradation [24, 25].
Metabolic acidosis may also have antianabolic effects.
Ammonium chloride–induced metabolic acidosis in nor-
mal subjects is associated with a significant reduction in
the fractional synthetic rate of muscle protein [26], as
well as a reduction in the fractional synthetic rate for al-
bumin [15]. Metabolic acidosis may also cause a state of
insulin resistance. In euglycemic clamp studies, ammo-
nium chloride–induced metabolic acidosis leads to im-
paired glucose metabolism as the result of reduced tissue
sensitivity to insulin [27]. Insulin resistance may in turn
have a detrimental effect on muscle protein metabolism.
The detrimental effects of metabolic acidosis on nitrogen
balance and protein metabolism are outlined in Figure 4.
Adverse effects of metabolic acidosis on bone disease
In patients with chronic kidney disease and patients
with end-stage renal disease on maintenance hemodial-
ysis, the reduction in net acid excretion may lead to a
net positive proton balance [28]. The accumulated acid
is buffered in the bone such that in the setting of uncor-
rected metabolic acidosis there is ongoing consumption
of bone buffers with dissolution of bone and release of
calcium and phosphorus [29, 30]. In vitro data demon-
strate that metabolic acidosis is associated with net cal-
cium efflux from bone. This net calcium efflux is due in
part to physiochemical dissolution of bone during the pro-
cess of proton buffering [31]. However, acidosis may also
lead to enhanced cell-mediated bone resorption. Acido-
sis is known to stimulate osteoclast function and inhibit
osteoblast function with a net effect favoring enhanced
bone resorption [32, 33]. In patients with chronic kid-
ney disease not treated with dialysis, severe metabolic
Brezina et al: Acid loading during sevelamer hydrochloride treatment S-43
Animal protein diet Sevelamer HCI
Dietary acid load
Inadequate bicarbonate
transfer during dialysis
CKD: Impaired renal
excretion of daily acid load
Metabolic acidosis
Osteoblast activity
Bone dissolution Cell-mediated
bone resorption
Worsening renal osteodystrophy
Chemical buffering of
accumulated H+
Osteoclast activity
PTH level
Fig. 5. Effects of metabolic acidosis on bone disease.
acidosis is associated with impaired bone mineralization
and an increased incidence of osteomalacia [30, 34–36].
Moreover, bone mineralization rate may increase follow-
ing correction of metabolic acidosis in these patients [30].
Metabolic acidosis may also indirectly affect bone dis-
ease via changes in parathyroid hormone (PTH). In non-
dialyzed patients with chronic kidney disease, there is
an inverse relationship between serum bicarbonate and
serum PTH levels [37]. In uremic patients on mainte-
nance hemodialysis, metabolic acidosis is also associated
with increased PTH levels [38]. Moreover, PTH levels de-
cline after correction of metabolic acidosis [39]. Correc-
tion of metabolic acidosis may thus retard the progression
of dialysis osteodystrophy [38]. It should also be noted
that metabolic acidosis and PTH may have synergistic
effects on bone such that in the presence of metabolic
acidosis, PTH stimulates substantially more net efflux
of calcium from bone, greater enhancement of osteo-
clast activity, and stronger inhibition of osteoblast activity
[40–41]. Thus, available evidence indicates that metabolic
acidosis may lead to worsening of secondary hyper-
parathyroidism and renal osteodystrophy (Fig. 5).
TREATMENT OF METABOLIC ACIDOSIS IN
PATIENTS ON MAINTENANCE HEMODIALYSIS
There is some evidence in patients on maintenance
hemodialysis that treatment of metabolic acidosis may
result in amelioration or improvement in renal os-
teodystrophy. One study in 21 patients on maintenance
hemodialysis found that a group of patients with acidosis
(total CO2 = 15 mmol/L) had progression of secondary
hyperparathyroidism both biochemically and on bone
biopsy compared with patients in the control group (to-
tal CO2 = 24 mmol/L) [38]. In a cross-sectional study
of 76 patients with chronic kidney disease not yet on
dialysis, those with normal transiliac bone biopsy had a
serum bicarbonate level of 23 mmol/L, while those pa-
tients with either mild or advance mixed renal osteodys-
trophy had serum bicarbonate levels less than 20 mmol/L
[42]. Furthermore, evidence suggests that the absence of
metabolic acidosis renders the therapy of osteodystrophy
with vitamin D metabolites more effective [36]. In chil-
dren with renal tubular acidosis, normalization of serum
bicarbonate is one component of successful return of nor-
mal growth parameters [43].
The recently published National Kidney Founda-
tion K/DOQI clinical practice guidelines for Bone
Metabolism and Disease in Chronic Kidney Disease rec-
ommend measurement and monitoring of the serum lev-
els of total CO2 in patients with chronic kidney disease
stages 3, 4, and 5, and in patients on maintenance
hemodialysis [44]. Therapeutic maneuvers to keep pre-
dialysis levels of total CO2 above 22 mmol/L are
recommended both to promote improvement in bone his-
tology [36] and to ameliorate excess protein catabolism
[45]. Increasing the bicarbonate level in the dialysate is
one therapeutic option. However, evidence indicates that
in patients treated with sevelamer hydrochloride, even
increasing the dialysate bicarbonate level to 40 mEq/L
may be inadequate to achieve K/DOQI guidelines for
total CO2. In one cross-sectional study of 30 patients
on maintenance hemodialysis treated with sevelamer hy-
drochloride for at least one year (mean 23 months, range
13 to 40 months), despite treatment with standard dial-
ysis bicarbonate of 40 mEq/L, mean serum bicarbonate
was 18.6 ± 2.7, and 77% of these patients had serum
bicarbonate less than 20 mEq/L [abstract; Ciampi MA
et al, J Am Soc Nephrol 13:586A, 2002]. In contrast, in pa-
tients treated with calcium-containing phosphate binders
the mean serum bicarbonate was 20.3 ± 1.8 mEq/L, and
only 36% of patients had bicarbonate levels less than
20 mEq/L.
Thus, to achieve and maintain the goal total CO2 above
22 mmol/L in patients treated with sevelamer hydrochlo-
ride, it may be necessary to provide supplemental alkali
salts such as sodium bicarbonate [44]. It should also be
noted that treatment with supplemental sodium bicar-
bonate might reduce the phosphate-binding efficacy of
sevelamer hydrochloride because the exogenous bicar-
bonate will compete with dietary phosphate for binding
to the anion exchange resin. It is also important to re-
member that use of exogenous alkali salts containing cit-
rate may increase the absorption of dietary aluminum
[46], thereby increasing the risk of aluminum-induced
bone disease and encephalopathy in patients with chronic
kidney disease. For this reason, alkalinizing therapy with
sodium citrate or other citrate alkali salts is contraindi-
cated in patients with advanced chronic kidney disease
or those with ESRD on maintenance hemodialysis.
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CONCLUSION
Hemodialysis patients treated with sevelamer hy-
drochloride consistently have lower serum bicarbonate
levels than patients treated with calcium-containing phos-
phate binders. This observation is unlikely to be related
solely to withdrawal of a source of base such as acetate
or carbonate. It may also be caused by an increased
dietary acid load during treatment with sevelamer hy-
drochloride. This notion is supported by preliminary
results from our laboratory, in which rats treated with
sevelamer hydrochloride had a fall in urine pH, as well
as an increase in urinary ammonium and calcium excre-
tion consistent with an increase in net acid excretion.
Chronic metabolic acidosis in maintenance dialysis pa-
tients is associated with major systemic effects, including
worsening of secondary hyperparathyroidism, net neg-
ative nitrogen and total body protein balance, and in-
creased risk of death. For that reason, the long-term risks
of worsening metabolic acidosis in hemodialysis patients
treated with sevelamer hydrochloride clearly deserve fur-
ther study. In the meanwhile, it is possible that reformula-
tion of sevelamer hydrochloride may be necessary so that
this phosphate-binding anion exchange resin contains less
chloride and more acetate or carbonate.
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